---
title: "WuXi AppTec Co., Ltd. (603259.SH) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/603259.SH/overview.md"
symbol: "603259.SH"
name: "WuXi AppTec Co., Ltd."
parent: "https://longbridge.com/zh-CN/quote/603259.SH.md"
datetime: "2026-04-04T16:39:07.278Z"
locales:
  - [en](https://longbridge.com/en/quote/603259.SH/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603259.SH/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603259.SH/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/603259.SH/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/603259.SH/overview.md)


# WuXi AppTec Co., Ltd. (603259.SH) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Life Sciences Tools and Services |
| 交易所 | CN Market |
| 地址 | No.5 Mashan Bridge, Binhu District, Wuxi City, Jiangsu Province |
| 官网 | [www.wuxiapptec.com.cn](https://www.wuxiapptec.com.cn) |

## 公司简介

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Ge Li(李革) | 董事长 & 总裁 & 首席执行官(CEO) |
| 韩敏 | 董事会秘书 & 公司秘书 & 授权代表 |
| 张朝晖 | 副总裁 |
| 施明 | 首席财务官 |
| Minzhang Chen(陈民章) | 联席首席执行官 |
| Steve Qing Yang(杨青) | 联席首席执行官 |
| 张远舟 | 环境、社会及管治委员会委员 |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| 香港中央结算(代理人)有限公司 | 17.11% | 2026-03-24 |
| 香港中央结算有限公司 | 6.58% | 2026-03-24 |
| G&C VI Limited | 4.36% | 2026-03-24 |
| G&C IV Hong Kong Limited | 3.19% | 2026-03-24 |
| 北京中民银孚投资管理有限公司-嘉兴宇祥投资合伙企业(有限合伙) | 2.65% | 2026-03-24 |
| G&C V Limited | 2.23% | 2026-03-24 |
| 中国工商银行-上证50交易型开放式指数证券投资基金 | 1.53% | 2026-03-24 |
| 中国工商银行股份有限公司-华泰柏瑞沪深300交易型开放式指数证券投资基金 | 1.37% | 2026-03-24 |
| G&C VII Limited | 1.15% | 2026-03-24 |
| 中国建设银行股份有限公司-易方达沪深300医药卫生交易型开放式指数证券投资基金 | 1.10% | 2026-03-24 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| Chemical Business | 36465846882 | 80.22% |
| Test Business | 4041701030 | 8.89% |
| Biology Business | 2677175030 | 5.89% |
| Discontinued Operations | 2035342035 | 4.48% |
| Others | 236100794 | 0.52% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "WuXi AppTec Co., Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Chemical Business",
        "ratio": 80.22
      },
      {
        "segment": "Test Business",
        "ratio": 8.89
      },
      {
        "segment": "Biology Business",
        "ratio": 5.89
      },
      {
        "segment": "Discontinued Operations",
        "ratio": 4.48
      },
      {
        "segment": "Others",
        "ratio": 0.52
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| Overseas | 37954185900 | 83.5% |
| China | 5466637900 | 12.03% |
| Discontinued Operations | 2035342000 | 4.48% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**